Retatrutide Providers in Florida

About Retatrutide

Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. In the Phase 2 TRIUMPH trial, participants on the highest dose lost an average of 24.2% of body weight over 48 weeks, with some Phase 3 cohorts reporting losses above 28%. Expected to file an NDA with the FDA in Q4 2026, retatrutide is widely anticipated to become the next major advance beyond tirzepatide for obesity and metabolic disease.